City Pedia Web Search

Search results

1. Results From The WOW.Com Content Network

2. Tesofensine - Wikipedia

   en.wikipedia.org/wiki/Tesofensine

   Phase IIB trial (TIPO-1) results reported in The Lancet [19] showed levels of weight loss over a 6-month period that were significantly greater than those achieved with any currently available drugs. Patients lost an average of 12.8 kg on the 1 mg dose, 11.3 kg on the 0.5 mg dose and 6.7 kg on the 0.25 mg dose, compared with a 2.2 kg loss in ...

3. New weight loss drugs are coming, and they could burn more ...

   www.aol.com/news/slew-weight-loss-drugs...

   In a phase 2 trial of people who were overweight or had obesity, Boehringer Ingelheim’s survodutide, which uses both GLP-1 and glucagon, led to weight loss of 19% at 46 weeks. Another phase 2 ...

4. Pfizer's twice-daily weight-loss pill discontinued due to ...

   www.aol.com/news/ozempic-without-injection...

   Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...

5. gamma-Hydroxybutyric acid - Wikipedia

   en.wikipedia.org/wiki/Gamma-Hydroxybutyric_acid

   gamma-Hydroxybutyric acid (GHB) (or γ-hydroxybutyric acid ), also known as 4-hydroxybutanoic acid is a naturally occurring neurotransmitter and a depressant drug. It is a precursor to GABA, glutamate, and glycine in certain brain areas. It acts on the GHB receptor and is a weak agonist at the GABA B receptor.

6. Zopiclone - Wikipedia

   en.wikipedia.org/wiki/Zopiclone

   Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine, specifically cyclopyrrolones, used to treat difficulty sleeping. Zopiclone is molecularly distinct from benzodiazepine drugs and is classed as a cyclopyrrolone. However, zopiclone increases the normal transmission of the neurotransmitter gamma-aminobutyric acid ...

7. Semaglutide linked to lower cognitive decline risk and ...

   www.aol.com/semaglutide-linked-lower-cognitive...

   According to recent research, semaglutide drugs, such as Ozempic and Wegovy, are linked to a lower risk of cognitive problems, as well as reduced cravings for nicotine.